An inpatient regimen for community-acquired pneumonia commonly includes a beta-lactam plus a macrolide. Which pairing illustrates this approach?

An inpatient regimen for community-acquired pneumonia commonly includes a beta-lactam plus a macrolide. Which pairing illustrates this approach?

• A. Ceftriaxone and azithromycin
• B. Amoxicillin alone
• C. Cefazolin alone
• D. Doxycycline and metronidazole

Answer: (A)

Inpatient treatment for community-acquired pneumonia is typically a beta-lactam antibiotic paired with a macrolide to cover both typical and atypical pathogens. The pairing of ceftriaxone (a beta-lactam) with azithromycin (a macrolide) fits this approach. Ceftriaxone provides strong activity against common CAP pathogens like Streptococcus pneumoniae and Haemophilus influenzae, while azithromycin covers atypicals such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella. Together, they broaden the coverage needed for hospitalized patients. Amoxicillin alone wouldn’t cover atypical organisms. Cefazolin lacks reliable activity against many CAP pathogens and provides no atypical coverage. Doxycycline with metronidazole combines an agent that may cover some atypicals with an anaerobe-focused partner and still misses the standard beta-lactam plus macrolide approach for inpatient CAP.

Inpatient treatment for community-acquired pneumonia is typically a beta-lactam antibiotic paired with a macrolide to cover both typical and atypical pathogens. The pairing of ceftriaxone (a beta-lactam) with azithromycin (a macrolide) fits this approach. Ceftriaxone provides strong activity against common CAP pathogens like Streptococcus pneumoniae and Haemophilus influenzae, while azithromycin covers atypicals such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella. Together, they broaden the coverage needed for hospitalized patients.

Amoxicillin alone wouldn’t cover atypical organisms. Cefazolin lacks reliable activity against many CAP pathogens and provides no atypical coverage. Doxycycline with metronidazole combines an agent that may cover some atypicals with an anaerobe-focused partner and still misses the standard beta-lactam plus macrolide approach for inpatient CAP.